A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer
Lists
Only you see this
BibTeX
@misc{hernando2024phase,
author = {Alberto Hernando and Ming Han and Olubukola Ayodele and Ben X. Wang and Farnoosh Abbas‐Aghababazadeh and María Vila-Casadesús and Enrique Sanz‐García and S.Y. Cindy Yang and Hal K. Berman and Ana Vivancos and Bernard Lam and Ilinca M. Lungu and Abdulazeez Salawu and Lee-Anne Stayner and Benjamin Haibe‐Kains and Philippe L. Bédard and Lisa Avery and Albiruni R. Abdul Razak and Trevor J. Pugh and Anna Spreafico and Lillian L. Siu and Aaron Hansen},
title = {{A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer}},
year = {2024},
doi = {10.2139/ssrn.4750763},
howpublished = {SSRN},
}Loading related content...